Objectives: Problems of vancomycin non-susceptible Staphylococcus aureus (VISA) and subsequent treatment failure are increasing. This study aimed to observe development and loss of vancomycin non-susceptibility, determine exposure time needed for resistance development, and follow mutations in the VraSR and GraSR two-component systems during these processes.
Introduction
Whilst vancomycin remains a frontline drug for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection, loss of susceptibility, characteristically involving an increase in MIC to around 8 mg/L, is associated with treatment failure. Vancomycin non-susceptible S. aureus (VISA) strains have altered cell walls preventing vancomycin reaching its target sites. 1, 2 These changes have been associated with mutations in regulatory genes vraS and graR, 3 -5 and, more recently, in rpoB. 6 However, most studies have investigated a single set of isogenic non-susceptible phenotypes (Mu3, Mu50 and Mu50V), 4 and no one mutation or set of mutations has been reliably associated with resistance. In particular, subsequent loss of non-susceptibility has been described in very few isolates. 4, 5 More work is required to identify the important determinants for non-susceptibility and the timescale over which these mutations occur. Identification of a consistent resistance marker may allow development of a molecular detection method. Patterns of development and loss of non-susceptibility were compared in 30 clinical MRSA isolates, and vraS, graR and rpoB were sequenced for mutations in strains of each of the patterns identified.
Materials and methods
The optimal conditions for developing non-susceptibility were determined by comparing the effects of time between passage, incubation temperature and atmospheric conditions. Initial vancomycin MICs for 30 clinical MRSA isolates were determined using the spiral gradient endpoint technique (SGE), which provides actual MIC concentrations rather 7 Additionally, SGE allows easy recognition of heterogeneous VISA (hVISA) sub-populations. The isolates, collected before commencement of therapy, were from consecutive patients suffering from bloodstream or skin and soft tissue infections. Isolates were incubated in brain heart infusion (BHI) broth (Oxoid, Basingstoke, UK) with vancomycin (Sigma-Aldrich, St Louis, MO, USA) at 50% initial MIC. After 48 h, MICs were re-determined, and the strains were passaged to fresh media. If the MIC had increased, the vancomycin concentration was increased to 50% of the new MIC level. This process was repeated every 48 h for 60 days. Mu50 4 (NRS1) was also passaged for 60 days to achieve the maximum vancomycin MIC in this strain (Mu50max). Isolates were passaged without vancomycin as a control.
Stability of non-susceptibility was then determined by passaging in vancomycin-free broth until the MIC reverted to 1 mg/L. Isolates were saved at five stages: a (initial strain with MIC ,1 mg/L), hVISA (MIC .2 and ,4 mg/L), VISA (MIC ≥4 mg/L), VISAmax (highest MIC) and V (MIC ≤1 mg/L or after 60 days). MICs of the 30 isolates plotted against time revealed six distinct patterns of non-susceptibility development and loss. One strain from each pattern was selected for genetic analysis. DNA was extracted from the selected isolates at the above designated stages, their unexposed controls, Mu3 (hVISA), Mu50 (VISA), Mu50max and MuV and, for comparison, a standard strain of MRSA (N315) that had not been subjected to resistance selection pressure. 4, 5 vraS, graR and rpoB were amplified, 6 and the products sequenced and compared with N315. mecA presence and SCCmec and agr types were determined in a and VISAmax isolates. vanA presence was investigated if the VISAmax MIC was ≥16 mg/L. PFGE was performed on the six strains at each stage. Growth rates in BHI, lysostaphin lysis and time for tube coagulase test positivity were determined. 8 Susceptibility to other antibiotics was compared in a, hVISA, VISAmax and V isolates.
Results
Using optimal induction conditions (378C in air; passage at 48 h intervals) all isolates developed non-susceptibility within 60 days, although the time required and the maximum MIC attained varied. AVISAmax of 20 mg/L was achieved in 6/30 strains. Six patterns of development and loss of non-susceptibility were observed; the most common, P3, was displayed by 18 isolates. In P1, VISA development was delayed until 54 days of exposure. After removal of vancomycin pressure, 29/30 isolates reverted to susceptible, the remaining isolate (P6) retaining an MIC of 20 mg/L (Table 1) . Control strains MICs remained unchanged throughout. Mu50 reached a maximum MIC of 15 mg/L at 54 days (Mu50max).
All isolates were initially susceptible to chloramphenicol, cotrimoxazole, daptomycin, fusidic acid, linezolid, quinupristin/dalfopristin, tigecycline and rifampicin, and resistant to ciprofloxacin and erythromycin. P1, P5 and P6 isolates were susceptible to gentamicin, but only P1 was clindamycin susceptible. After induction, resistance to fusidic acid, quinupristin/dalfopristin and co-trimoxazole was observed for several isolates, but only P6 became resistant to rifampicin. Of the VISAmax isolates, all retained high-level oxacillin resistance and displayed daptomycin resistance, four demonstrated linezolid resistance, and all remained susceptible to tigecycline. After loss of vancomycin resistance, all but P6 reverted to their initial susceptibility patterns (Table 1) .
VISAmax strains were most resistant to lysostaphin lysis and required the longest times for coagulation detection (Table 1) . Growth rates decreased with increasing non-susceptibility, with doubling times varying from 30 -170 min (VISA) and 37 -200 min (VISAmax).
All isolates harboured mecA throughout and were SCCmec type III, with 29/30 being agr type 1 (one P3 was non-typeable). vanA was not detected. P2, P3 and P4 were indistinguishable (type A) by PFGE, with P5 (A1) and P6 (A2) differing by only one band. P1 differed considerably (type B). Isolates retained the same banding patterns throughout.
Analysis of vraS and graR indicated that mutations occurred concomitant with changes in susceptibility, although actual mutations varied between strains. Mutations M1K in VraS and D148Q in GraR were seen in strains attaining an MIC of 20 mg/L (Table 2) . Only silent mutations were observed in the RNA polymerase b subunit (RpoB) (at amino acids 630 and 658) in all five stages in all strains except P3, which just displayed the amino acid 658 mutation. In contrast, an H481Y mutation was observed in Mu50, Mu50max and MuV. No mutations in the genes of interest were observed in non-exposed controls.
P1
The initial isolate displayed mutations for stop codons in both vraS and graR, which, on day 54, were replaced by amino acid codons, with a further mutation in GraR (S172L). These changes were accompanied by an abrupt rise in MIC, bypassing the hVISA stage. On loss of non-susceptibility, P1 isolates reverted to the initial configuration, including stop codons.
P2 and P3
Development of non-susceptibility was fairly rapid and accompanied by mutations on vraS and graR. P2 and P3 reached VISAmax MICs similar to that of Mu50max (15 mg/L). Loss of non-susceptibility was accompanied by formation of stop codons in both vraS and graR (Table 2) .
P4, P5 and P6
Whilst P4 rapidly gained non-susceptibility, all these strains achieved a VISAmax of 20 mg/L, with mutations at amino acid 1 in VraS at the hVISA stage, and D148Q in GraR initially. D148Q was lost at the V stage in P4 and P5, but retained in P6, which was a stable VISA phenotype. Return to susceptibility was associated with formation of stop codons in vraS in both P4 and 5, and in GraR for P5. Stop codons were not observed in P6.
Discussion
This report demonstrated the important role of stop codons in vraS and graR during development and loss of non-susceptibility. A stop codon was also present in vraS of MuV. 4 The presence of a stop codon associated with susceptibility changes was also described in tcaA.
9 Additional mutations, M1K in VraS and D148Q in GraR, may be associated with increased resistance (.16 mg/L), the latter mutation having been previously described in non-susceptible strains. an extended induction period, all 30 strains developed nonsusceptibility by 54 days, with a median time for VISA development of 29 days. However, these strains were sourced from one hospital and mainly belonged to one clonal type (the most common in Hong Kong), and may not be representative of all MRSA strains in their response to vancomycin exposure. Development of non-susceptibility was accompanied by increased resistance to non-glycopeptide antibiotics, possibly due to the thickened cell wall affecting permeability. 2 Crossresistance to daptomycin in hVISA/VISA has been attributed to the altered cell wall acting as a common impediment to daptomycin and vancomycin penetration. 6 On reversion to vancomycin susceptibility (and presumably reduced cell wall thickness), susceptibilities for all drugs were restored to pre-vancomycin patterns, while the stable VISA strain (P6) retained resistance.
Only tigecycline was active against all VISAmax isolates. Its lower molecular weight (586 kDa) relative to vancomycin (1485 kDa) and daptomycin (1620 kDa) may facilitate cell wall penetration.
As prolonged exposure to vancomycin increased risk of resistance to both glycopeptides and other anti-MRSA agents, it may be prudent to change to another antibiotic as soon as any elevation in MIC is observed, to reduce the likelihood of treatment failure.
Although mutations in the VraSR and GraSR two-component systems differed between the representative strains, it appeared that, as with previous reports, 3 -5 mutation in vraS was essential for initial non-susceptibility development whilst those in graR contributed to further MIC increase. It has been suggested that mutations in graR (S79F or D148Q) are essential for development of vancomycin intermediate resistance. 3 Although S79F was not observed in our non-susceptible strains, D148Q occurred in all strains reaching an MIC of 20 mg/L. These isolates showed the changed amino acid 148 at a, and, additionally, displayed a mutation at amino acid 1 in VraS. These changes may be essential in acquiring and maintaining high-level resistance. 5 In the isolate with delayed resistance development, the MIC change was accompanied by loss of stop codons in both vraS and graR, suggesting that the presence of these stop codons may prevent the process leading to alterations in the cell wall. This is in contrast to the effects of stop codons in tcaA, which increase non-susceptibility. 9 There has been limited investigation of genetic change in resistance loss, other than for Mu50. 4 There was an 18 month delay between isolation of Mu50 in clinical failure and its subsequent re-isolation in a susceptible form (Mu50V) from the same patient. Mu50V had lost the mutation in graR, reverting to the vancomycin susceptible gene configuration. 4 With one exception, removal of selective pressure from our strains led to reversion to initial MIC levels. This is likely to be associated with the fitness cost required to maintain a thickened cell wall. During nonsusceptibility loss, there were changes in both vraS and graR resulting in stop codons. This suggests rapid correction to reduce cell wall synthesis, reflected in the prompt reduction in MICs. In Mu50V, a stop codon was observed in vraS, but not in graR. Longer recovery time may lead to reversion to wild-type, as had occurred in Mu50V. 4 In contrast to reverted strains, such stop codons were absent in our stable VISA strain, suggesting their non-appearance in the absence of selective pressure may result in a stable phenotype. Although the VraS stop codons were mainly in the C-terminal domain, rather than the N-terminal ligand-binding domain, their presence in all the reverted strains suggests they may affect the function of VraS.
In contrast to other reports, 6 we observed no changes in rpoB during vancomycin non-susceptibility development. This suggests that either change in rpoB is not essential or that alternative pathways may exist for resistance development. Rifampicin resistance developed only in P6, although, as no mutation arose in rpoB, resistance may have been associated with cell wall permeability rather than genetic change. Other genetic changes, including mutations in walKR, yvqF and clpP, 1 have been associated with vancomycin non-susceptibility, and it is likely several mechanisms are involved.
This study demonstrated that prolonged vancomycin exposure leads to development of VISA, including formation of stable phenotypes. It supports findings that mutations in vraS followed by mutations in graR are important in development of VISA, 1, 3 and suggested that stop codons in vraSR and graSR play an important role in both delaying VISA development and during loss of non-susceptibility.
